Monotherapy with infusion therapies – useful or not?

Petra Bago Rožanković, Anders Johansson, Klivényi Péter, Ivan Milanov, Per Odin

Research output: Contribution to journalReview articlepeer-review

Abstract

Infusion pump-based therapies are an effective treatment option for patients with advanced Parkinson´s disease. Achieving monotherapy with infusion-based therapies could simplify the treatment regimen, provide better medication adherence, reduce adverse events and drug interactions. This review presents the literature data on the efficacy, safety, and achievability of monotherapy with all available infusion-based therapies, including apomorphine, levodopa-carbidopa-intestinal gel (LCIG), levodopa-entacapone-carbidopa intestinal gel (LECIG), and foslevodopa-foscarbidopa (LDp/CDp). In summary, monotherapy is achievable and effective in most patients on intestinal levodopa infusion therapy and in some patients on apomorphine infusion. There is a need for further investigation of monotherapy compared to polytherapy, especially in new pump treatment options (LECIG and LDp/CDp). Future research should reveal which patients on infusion-based therapies could benefit from monotherapy, including identification of potential baseline predictors of achieving monotherapy in patients treated with specific infusion-based therapies.

Original languageEnglish
Pages (from-to)1341-1348
Number of pages8
JournalJournal of Neural Transmission
Volume131
Issue number11
DOIs
Publication statusPublished - 2024 Nov

Subject classification (UKÄ)

  • Neurology

Free keywords

  • Advanced parkinson´s disease
  • Infusion therapies
  • Monotherapy

Cite this